did the fda ban compounded tirzepatide Compounded' weight-loss drugs are a growing problem for state regulators • Stateline FDA is moving to restrict

Existing findings are largely derived from preclinical and exploratory models, and the mechanistic scope of these observations remains under ongoing investigation

This issue covers a broad range of topics: Original research includes a nationwide Swedish study on antithrombotic strategies in patients with MI and atrial fibrillation, a win ratio re-analysis of the ADVANCE trial in type 2 diabetes, real-world evidence on SGLT2 inhibitors and sacubitril/valsartan in heart failure, a comparison of eplerenone versus spironolactone in HFrEF, and a retrospective cohort study on SSRI use and bleeding risk in patients on dual antiplatelet therapy after PCI

Royal Mail Tracked24 delivery is available and free UK shipping applies on orders over 50

B cells B cells, originating from the bone marrow, are responsible for driving the humoral arm of adaptive immunity

The cardiovascular system in growth hormone excess and growth hormone deficiency